Background The pharmacokinetics and appropriate dose regimens of favipiravir are
unknown in hospitalized influenza patients; such data are also needed to determine dosage …

Favipiravir (T-705; 6-fluoro-3‑hydroxy-2-pyrazinecarboxamide) is an orally bioavailable
nucleoside analog that selectively inhibits the PB1 subunit of the RNA-dependent RNA …

Background The pharmacokinetics of oral favipiravir and the relationships of plasma
concentrations to antiviral effects are incompletely studied in influenza. Methods Serial …

Background We conducted double-blind, placebo-controlled trials assessing the efficacy
and tolerability of favipiravir in acute influenza. Methods Otherwise healthy adults with …

Background A synergistic effect of combination therapy with favipiravir and oseltamivir has
been reported in preclinical models of influenza. However, no data are available on the …

As reviewed by Cao et al., the availability of results of previous research studies helped in
prioritizing clinical trials for Remdesivir [1]. The molecule was covered in WHO's Director …

Background Favipiravir is used to treat influenza, and studies demonstrate that it has
antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Favipiravir is an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase that
is approved for treatment of influenza in Japan. We conducted a prospective, randomized …

An outbreak of 2019‐nCoV infection has spread across the world. No specific antiviral drugs
have been approved for the treatment of COVID‐2019. In addition to the recommended …

Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro …